



Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

Press Release
January 20, 2015

BSE: 532531
NSE: STAR

Strides Arcolab signs Agreement with Gilead Sciences to Manufacture and Distribute Tenofovir Alafenamide (TAF) based HIV treatments in 112 Developing Countries

Bangalore, January 20, 2015: Strides Arcolab Limited (Strides) today announced that it has entered into a licensing agreement with Gilead Sciences, Inc. under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs.

The license being granted to Strides extends to 112 countries, which together account for more than 30 million people living with HIV.

As part of the licensing agreement, pending U.S. Food and Drug Administration (US FDA) approval of the Gilead product, Strides will receive a technology transfer from Gilead, enabling Strides to manufacture low-cost versions of TAF for developing countries.

TAF is a novel nucleotide reverse transcriptase inhibitor that has demonstrated high antiviral efficacy at a dose 10 times lower than Gilead's Viread® (tenofovir disoproxil fumarate), as well as an improved renal and bone safety profile.

TAF and TAF-based regimens are investigational products in the United States and have not yet been determined safe or efficacious in humans.

About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products. The Company has 8 manufacturing facilities presence in more than 75 countries in developed and emerging markets. Additional information is available at the Company's website at www.stridesarco.com. For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mohan Kumar, CEO –Strides Pharma Global Pte Ltd +91 80 6784 0748	Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.in
Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745	K Priya: +91 9535425418 priya@fortunapr.in